EN
EN
2026-7-23
Recently, Shenzhen Zhongjia Biomedical Technology Co., Ltd. (“Zhongjia Biomedical”) delivered good news again – its self-developed serum-free hematopoietic stem cell basal medium has officially obtained a Drug Master File (DMF) filing issued by the U.S. Food and Drug Administration (FDA), with filing number 044283. This is the fourth medium product from Zhongjia Biomedical to receive an FDA DMF filing, marking another step forward in our R&D and compliance capabilities for critical raw materials used in cell therapy, and providing global customers with higher-quality, more compliant supply chain options.
Filing Overview
DMF Number: 044283
Filing Type: Type II
Product Name: Serum-free hematopoietic stem cell basal medium
Applications: Hematopoietic stem cell expansion, culture, and cell therapy-related research and applications
Core Product Highlights
Serum-free formulation: avoids batch differences and safety risks caused by animal-derived components, making it more suitable for clinical-grade applications.
Efficient expansion support: validated to stably support ex vivo expansion and functional maintenance of hematopoietic stem cells.
Compliance first: the DMF filing will help customers cite relevant data during FDA submissions, accelerating IND, NDA and other approval processes.
Continuous Dedication, Empowering the Industry
As a leading domestic supplier of cell culture raw materials, Zhongjia Biomedical stays committed to the principles of “technical excellence and quality safety”, continuously launching core raw materials that meet international standards. To date, four of our medium products have received FDA DMF filings, covering key application directions such as mesenchymal stem cells, immune cells, and hematopoietic stem cells. We understand that the success of cell therapy products relies on stable, traceable, and compliant raw material support.


Zhongjia Biomedical will continue to provide compliant, stable and efficient medium solutions for cell therapy enterprises worldwide.
Focus on MLD: Why Should This Rare Leukodystrophy Be Seen Earlier?
2026-10-23
Can Alzheimer’s Risk Be Reduced? WHO Guidance Highlights Modifiable Dementia Risk Factors
2026-9-28
Alzheimer's Treatment Advances: From Amyloid to Tau Multi-Target Research
2026-9-28
New Progress in Early Alzheimer's Screening: Blood Tests Become an Important Research Direction
2026-9-28
Great News! Another Zhongjia Medium Gets FDA DMF Filing
2026-7-23